Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
08/2012
08/21/2012US8246961 Powder composition, method for producing the same, and food composition, cosmetic composition and pharmaceutical composition containing the same
08/21/2012US8246951 Collagenolytic active enzyme containing compositions, and their use in the dental field
08/21/2012US8246949 Methods and devices for sustained in-vivo release of an active agent
08/21/2012US8246934 Respiratory dispersion for metered dose inhalers comprising perforated microstructures
08/21/2012US8246930 Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
08/21/2012CA2688047C Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration
08/21/2012CA2633413C Antibodies against tumor-associated antigenic target (tat) polypeptides
08/21/2012CA2620594C Pharmaceutical composition having improved disintegratability
08/21/2012CA2565097C Pharmaceutical composition comprising oxoplatin, the salts and derivatives thereof
08/21/2012CA2562190C Novel antiviral pharmaceutical composition
08/21/2012CA2499686C Solubilising polysaccharides substituted with hydrophilic and hydrophobic groups
08/21/2012CA2495830C The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
08/21/2012CA2459794C Vascular occlusion solid-phase agent with immobilised platelet binding agent
08/21/2012CA2449284C Alpha-fetoprotein peptides and uses thereof
08/21/2012CA2445239C Drug delivery matrices to enhance wound healing
08/21/2012CA2412759C Injectable solution of an lhrh antagonist
08/21/2012CA2312975C Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
08/21/2012CA2288143C Activated protein c formulations
08/21/2012CA2233924C Novel stable liquid paracetamol compositions, and method for preparing same
08/16/2012WO2012109642A1 Aqueous extraction methods for high lipid microorganisms
08/16/2012WO2012109473A2 Detection of endotoxins
08/16/2012WO2012109429A2 Lyophilized formulations
08/16/2012WO2012109387A1 Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
08/16/2012WO2012109243A2 Method of treating intercellular barrier dysfunction
08/16/2012WO2012109203A1 Adjuvant compositions with 4-ibbl
08/16/2012WO2012109112A2 Polymer-carbohydrate-lipid conjugates
08/16/2012WO2012109052A1 Polymer-carbohydrate-lipid conjugates
08/16/2012WO2012108960A2 Ghrelin mimetic polypeptide hapten immunoconjugates having improved solubility and immunogenicity and methods of use thereof
08/16/2012WO2012108863A1 Compositions and methods for controllably delivering an agent
08/16/2012WO2012108648A2 Method of preparing iron oxide nanoparticles coated with hydrophilic material, and magnetic resonance imaging contrast agent using the same
08/16/2012WO2012108631A2 Pharmaceutical compositions comprising revaprazan-containing nanoparticles and processes for the preparation thereof
08/16/2012WO2012108614A1 Temperature-sensitive polyethylene glycol / polyester block copolymer in which bioactive functional group is introduced into side chain thereof
08/16/2012WO2012108606A1 Sol-gel transition chitosan-polymer composite and use for same
08/16/2012WO2012108489A1 Aqueous composition having improved hydrophilic drug penetrability
08/16/2012WO2012108266A1 Orally disintegrating tablet and production method therefor
08/16/2012WO2012107585A1 Novel concentrated and stable topical antiparasitic compositions
08/16/2012WO2012107579A1 Hydrophobic modified peptides and their use for liver specific targeting
08/16/2012WO2012107575A1 Novel formulations for dermal, transdermal and mucosal use 2
08/16/2012WO2012107573A1 Novel formulations for dermal, transdermal and mucosal use 3
08/16/2012WO2012107565A1 Novel antifungal composition
08/16/2012WO2012107564A1 Novel formulations for dermal, transdermal and mucosal use 1
08/16/2012WO2012107417A1 Mutant interleukin-2 polypeptides
08/16/2012WO2012107416A2 Improved immunotherapy
08/16/2012WO2012107356A1 Aqueous pharmaceutical composition for preventing and/or treating allergically irritated nasal mucosa and use thereof
08/16/2012WO2012106751A1 Artificial oil bodies
08/16/2012WO2012087051A3 Microparticles containing physiologically active peptide, method for preparing the same, and pharmaceutical composition comprising the same
08/16/2012WO2012084754A3 Pharmaceutical glp-1 compositions having an improved release profile
08/16/2012WO2012080984A3 Controlled-release pharmaceutical tablet for oral administration
08/16/2012WO2012075443A9 Methods for delivering clonidine compositions in a biodegradable polymer carrier and local steriods to a target tissue site
08/16/2012WO2012073245A8 Conjugates of a phospholipid and a drug for the treatment of inflammatory bowel disease
08/16/2012WO2012071324A3 Pharmaceutical compositions
08/16/2012WO2012054447A3 Use of storage stable viscous phospholipid depot to treat wounds
08/16/2012WO2012037380A3 Formulations of guanylate cyclase c agonists and methods of use
08/16/2012WO2012031164A3 Drug delivery by carbon nanotube arrays
08/16/2012WO2012028276A3 Device for metering an acid-containing composition
08/16/2012WO2012020108A3 Multimeric inhibitors of viral fusion and uses thereof
08/16/2012WO2012016703A3 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
08/16/2012WO2012016698A3 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
08/16/2012WO2012016697A3 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
08/16/2012WO2011154724A9 Injectable flowable composition comprising buprenorphine
08/16/2012WO2011134979A9 Stable aqueous mia/cd-rap formulations
08/16/2012US20120208897 Method for preparing acetylated derivatives of an amylaceous material
08/16/2012US20120208896 Amino acid derivatives and absorable polymers therefrom
08/16/2012US20120208895 Composite material with properties of self-healing and release of active ingredients, for biomedical applications
08/16/2012US20120208854 Therapeutic combination
08/16/2012US20120208845 Agonists and Antagonists of Human Bitter Taste Receptor TAS2R49 and Uses Thereof
08/16/2012US20120208832 Process for converting a solid (meth)acrylate copolymer into a dispersed form by means of a dispersing agent
08/16/2012US20120208780 Hybrid nanomaterials consisting of pseudorotaxanes, pseudopolyrotaxanes, rotaxanes, polyrotaxanes, nanoparticles and quantum dots
08/16/2012US20120208754 Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
08/16/2012US20120208721 Novel anti-igf-ir and/or anti-insulin/igf-i hybrid receptors antibodies and uses thereof
08/16/2012US20120208701 Polymers, compositions and methods of use for foams, laundry detergents, shower rinses and coagulants
08/16/2012US20120208023 Bioactivation of particles
08/16/2012US20120207929 Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
08/16/2012US20120207799 Oral delivery vehicle and material
08/16/2012US20120207789 Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
08/16/2012US20120207781 Dimensional analysis of saccharide conjugates with gpc & sec mals
08/16/2012US20120207779 Anaplasma phagocytophilum (Aph) Antigens and Antibodies Specific for Anaplasma
08/16/2012US20120207738 Pretreatment of Post Exposure Treatment for Exposure to a Toxic Substance by Pulmonary Delivery (Inhaler) of a Bioscavenger
08/16/2012CA2827082A1 Methods of treating macular edema using antiedema therapeutics
08/16/2012CA2827033A1 Lyophilized formulations
08/16/2012CA2826853A1 Ghrelin mimetic polypeptide hapten immunoconjugates having improved solubility and immunogenicity and methods of use thereof
08/16/2012CA2826741A1 Novel antifungal composition
08/16/2012CA2826629A1 Artificial oil bodies
08/16/2012CA2826582A1 Adjuvant compositions with 4-1bbl
08/16/2012CA2824333A1 Novel formulations for dermal, transdermal and mucosal use 1
08/16/2012CA2824253A1 Mutant interleukin-2 polypeptides
08/16/2012CA2824252A1 Improved immunotherapy
08/15/2012EP2486944A1 Magnetic nanoparticles
08/15/2012EP2486943A1 Pharmaceutical composition for the prophylaxis and treatment of infectious and non-infectious diarrhoea
08/15/2012EP2486942A1 Compositions comprising azelastine and methods of use thereof
08/15/2012EP2486941A1 Human antibodies that bind CXCR4 and uses thereof
08/15/2012EP2486933A1 Monomethylvaline compounds conjugated with antibodies
08/15/2012EP2486918A2 Pharmaceutical composition with both immediate and extended release characteristics
08/15/2012EP2486917A1 Coating film, and granules and tablets each utilizing same
08/15/2012EP2486916A1 Human growth hormone formulations
08/15/2012EP2486915A1 Topical pharmaceutical compositions comprising flurbiprofen and methylsulfonylmethane
08/15/2012EP2486061A1 Compositions and methods for the transport of therapeutic agents
08/15/2012EP2486023A1 Potent conjugates and hydrophilic linkers
08/15/2012EP2485998A1 Method for preparing a composition comprising a compound based on vanillin and ethyl vanillin, resulting composition and uses thereof
08/15/2012EP2485769A1 Delivery agent
1 ... 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 ... 1712